A schizophrenia research expert weighs in on the recent announcement concerning SPG302 for the treatment of individuals with schizophrenia.

What percentage of 2025 psychiatric pipeline news was positive vs negative? What disease states are most prominently featured in recent research? Learn more in this exclusive article.

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

Yesterday marked a somber National Doctors’ Day…

In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.

In honor of World Bipolar Day, our Mood Disorders Section Editor shares his favorite clinical pearls for treating bipolar disorder.

Here are highlights from this week in Psychiatric Times, including positive clinical trial news for an ADHD treatment and an exclusive interview on the joint statement defending psychotropic medication safety.

In this CME article, learn more about the common neuropsychiatric sequelae of post-acute sequelae of COVID-19, the underlying neurobiological mechanisms, and evidence-based treatments and interventions.

The LGBTQIA+ community has faced marginalization and stereotyping in media, including video games. Let’s examine the intersection of identity, mental health, and video gaming.

"Was this what Rome felt like toward the end? When the colosseums filled with gladiators stirred the masses into a frenzy."

Get ready for our new video series, "Psyched Perspectives"!

A social psychiatrist who stays on the ethical way.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.

Motherhood: what is truth vs idealized narrative?

After 40 years, Psychiatric Times is still your go-to resource for all things psychiatry. Just ask our Mood Disorders Section Editor.

Is the real March madness gambling?

"All redeeming Nature knows, You cannot stop the spring."

How can we prevent the transmission of intergenerational trauma, which persists?

How do your fellow clinicians feel about ethical quandaries in psychiatry? Find out here.

Learn more about key findings on sex differences in cognition, exploring the possible causes and implications for clinical practice.

While the removal of the REMS requirement can be liberating, appropriate monitoring for patients with schizophrenia is still of the utmost importance.

A psychiatrist reflects on the challenges we weather and the enduring search for hope and unity.

Disruptions to cognitive control, as well as to emotional processes, are implicated in a wide range of psychiatric disorders.

Our Mood Disorders Section Editor shares what treatments in the pipeline he is most excited about, including kappa opioid receptor antagonists.